Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 switch-over study of PRX-102 every 4 weeks in Fabry disease patients on enzyme replacement therapy
2017-001528-23Phase 3Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Jun 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Protalix BioTherapeutics. Primary endpoint: Safety endpoints. Started Jun 2017; status: completed.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2017-001528-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001528-23.